Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment

Tsung-Ta Chiang,Ming-Hsien Chiang,Hung-Jen Tang,Zhi-Yuan Shi,Mao-Wang Ho,Chia-Hui Chou,Shang-Yi Lin,Po-Liang Lu,Ting-Shu Wu,Shian-Sen Shie,Jien-Wei Liu,Feng-Yee Chang,Yin-Ching Chuang,Fu-Der Wang,Ya-Sung Yang

DOI: https://doi.org/10.1007/s10096-024-04892-x

2024-07-13

European Journal of Clinical Microbiology & Infectious Diseases

Abstract:Infections caused by Klebsiella pneumoniae are common and result in high mortality rates. In vitro studies demonstrated the potency of cefoperazone/sulbactam (CPZ/SUL) against Klebsiella pneumoniae . However, the clinical efficacy of CPZ/SUL for the treatment of K. pneumoniae bacteremia has not been studied.

infectious diseases,microbiology